EMD 201
Alternative Names: EMD-201Latest Information Update: 19 Oct 2022
At a glance
- Originator Emendo biotherapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Retinitis pigmentosa
Most Recent Events
- 19 Oct 2022 Preclinical trials in Retinitis pigmentosa in USA (Parenteral) (Emendo biotherapeutics pipeline, October 2022)
- 16 Dec 2020 EMD 201 is available for licensing as of 16 Dec 2020. https://emendobio.com/our-technology/
- 16 Dec 2020 Early research in Eye disorders in USA (Parenteral) before December 2020 (Emendo biotherapeutics pipeline, December 2020)